Mar 13th 2013 - Edison Investment Research today published a report on GW Pharmaceuticals (GWP.L, LSE:GWP, LON:GWP) entitled "Stirring The R&D Pot". In summary, the report says:
GW is advancing a broad pipeline of early-stage cannabinoid therapies targeting cancer, metabolic and central nervous system (CNS) diseases. These five programmes (three funded by Otsuka) are based on strong preclinical data and/or promising clinical results. In 2013, we expect substantial pipeline progress with Phase II trial starts, Phase II readouts, initial human trials and potential Otsuka licensing deals. All this offers pure upside to our DCF valuation of £195m or £1.46p/share.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »